Is there room for another personal genomics company? That's the question Daniel MacArthur asks on the news that Australia-based Lumigenix recently launched and will offer its genetic test for $470, slightly more than competitor 23andMe. The biggest obstacles, he writes, are its second-to-market status and the anti-genetic testing climate in Australia.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.